Skip to main content

Table 5 BCR-ABL1 KD mutations that influence the selection of second- or third-generation TKIs

From: Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges

T315I

Ponatinib

F317L/V/I/C, T315A

Nilotinib, bosutinib* (or ponatinib if the patient failed or was unable to tolerate first and second-generation TKIs)

V299L

Nilotinib (or ponatinib if the patient failed or was unable to tolerate first and second-generation TKIs)

Y253H, E255V/K, F359V/I/C

Dasatinib, bosutinib* (or ponatinib if the patient failed or was unable to tolerate first and second-generation TKIs)

  1. *There is very limited data available on mutations associated with clinical resistance to bosutinib in vivo. Some in vitro data suggested that the E255K and, to a lesser extent, the E255V, might be poorly sensitive to bosutinib [120]
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us